暂无分享,去创建一个
Andreu Vall | Andreas Mayr | Markus Hofmarcher | Elisabeth Rumetshofer | Peter Ruch | Philipp Renz | Johannes Schimunek | Philipp Seidl | Michael Widrich | Sepp Hochreiter | Gunter Klambauer | S. Hochreiter | Michael Widrich | Andreu Vall | G. Klambauer | Andreas Mayr | M. Hofmarcher | Elisabeth Rumetshofer | Philipp Renz | Philipp Seidl | Peter Ruch | Johannes Schimunek | Sepp Hochreiter
[1] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[2] Anne E Carpenter,et al. Repurposing High-Throughput Image Assays Enables Biological Activity Prediction for Drug Discovery. , 2018, Cell chemical biology.
[3] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[4] Chao Liu,et al. Potential Inhibitors Targeting RNA-Dependent RNA Polymerase Activity (NSP12) of SARS-CoV-2 , 2020 .
[5] Jun Zhang,et al. Virtual Screening and Molecular Dynamics on Blockage of Key Drug Targets as Treatment for COVID-19 Caused by SARS-CoV-2 , 2020 .
[6] Hualiang Jiang,et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors , 2020, bioRxiv.
[7] Sepp Hochreiter,et al. Accurate Prediction of Biological Assays with High-Throughput Microscopy Images and Convolutional Networks , 2019, J. Chem. Inf. Model..
[8] Lixia Chen,et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.
[9] Heidi Ledford. One drug, two targets , 2009 .
[10] An Hong,et al. Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2 , 2020, Journal of biomolecular structure & dynamics.
[11] Günter Klambauer,et al. DeepTox: Toxicity Prediction using Deep Learning , 2016, Front. Environ. Sci..
[12] Joanna Collison. Two targets are better than one , 2019, Nature Reviews Rheumatology.
[13] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[14] John Platt,et al. Probabilistic Outputs for Support vector Machines and Comparisons to Regularized Likelihood Methods , 1999 .
[15] Sepp Hochreiter,et al. Fréchet ChemNet Distance: A Metric for Generative Models for Molecules in Drug Discovery , 2018, J. Chem. Inf. Model..
[16] Jürgen Schmidhuber,et al. Long Short-Term Memory , 1997, Neural Computation.
[17] M. Farooq,et al. In Silico Discovery of Novel Inhibitors Against Main Protease (Mpro) of SARS-CoV-2 Using Pharmacophore and Molecular Docking Based Virtual Screening from ZINC Database , 2020 .
[18] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[19] Joseph Gomes,et al. MoleculeNet: a benchmark for molecular machine learning† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc02664a , 2017, Chemical science.
[20] Piero Procacci,et al. Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling , 2020 .
[21] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..
[22] Friedrich Rippmann,et al. Interpretable Deep Learning in Drug Discovery , 2019, Explainable AI.
[23] Shi Yulong,et al. D3Similarity: A Ligand-Based Approach for Predicting Drug Targets and for Virtual Screening of Active Compounds Against COVID-19 , 2020 .
[24] Hugo Ceulemans,et al. Large-scale comparison of machine learning methods for drug target prediction on ChEMBL† †Electronic supplementary information (ESI) available: Overview, Data Collection and Clustering, Methods, Results, Appendix. See DOI: 10.1039/c8sc00148k , 2018, Chemical science.
[25] Matthias Rarey,et al. Machine Learning in Drug Discovery , 2018, Journal of Chemical Information and Modeling.
[26] K. Tennekoon,et al. Virtual Screening of Inhibitors Against Spike Glycoprotein of 2019 Novel Corona Virus: A Drug Repurposing Approach , 2020 .
[27] David Weininger,et al. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..
[28] Liangzhong Lim,et al. Identification of a Zika NS2B-NS3pro pocket susceptible to allosteric inhibition by small molecules including qucertin rich in edible plants , 2016, bioRxiv.
[29] Markus A. Lill,et al. Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds , 2020 .
[30] Eli Reuveni,et al. Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance , 2017, Drug design, development and therapy.
[31] F. Cheng,et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.
[32] Artem Cherkasov,et al. Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds , 2020, Molecular informatics.
[33] David A. Scott,et al. An open-source drug discovery platform enables ultra-large virtual screens , 2020, Nature.
[34] Kwok-Yin Wong,et al. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. , 2020, F1000Research.